Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer
Authors:
- Fanny DaoFDFanny Dao
- Nadim Bou ZgheibNZNadim Bou Zgheib
- Sarah E. FergusonSFSarah E. Ferguson
- Paul J. SabbatiniPSPaul J. Sabbatini
- Martee L. HensleyMHMartee L. Hensley
- Katherine M. Bell-McGuinnKBKatherine M. Bell-McGuinn
- Jason KonnerJKJason Konner
- William P. TewWTWilliam P. Tew
- Carol AghajanianCACarol Aghajanian
- Dennis S. ChiDCDennis S. Chi
- 1 June 2012
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 125 (3) , 621-624
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Phase II Study of Intraperitoneal Paclitaxel Plus Cisplatin and Intravenous Paclitaxel Plus Bevacizumab As Adjuvant Treatment of Optimal Stage II/III Epithelial Ovarian CancerJournal of Clinical Oncology, 2011
- Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trialThe Lancet, 2009
- Intraperitoneal Cisplatin and Paclitaxel in Ovarian CancerNew England Journal of Medicine, 2006
- Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approachGynecologic Oncology, 2004
- Phase III Trial of Standard-Dose Intravenous Cisplatin Plus Paclitaxel Versus Moderately High-Dose Carboplatin Followed by Intravenous Paclitaxel and Intraperitoneal Cisplatin in Small-Volume Stage III Ovarian Carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology GroupJournal of Clinical Oncology, 2001
- Phase I Trial of Escalating Doses of Paclitaxel Combined With Fixed Doses of Cisplatin and Doxorubicin in Advanced Endometrial Cancer and Other Gynecologic Malignancies: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2001
- Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian CancerNew England Journal of Medicine, 1996
- European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.Journal of Clinical Oncology, 1994
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958